Barbara Rath
Overview
Explore the profile of Barbara Rath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1300
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nigro M, Valenzuela C, Arancibia F, Cohen M, Lam D, Maves R, et al.
ERJ Open Res
. 2024 Nov;
10(6).
PMID: 39534773
Background: Long COVID is a heterogeneous clinical syndrome characterised by a variety of reported symptoms and signs. Its clinical management is expected to differ significantly worldwide. Methods: A survey-based study...
2.
Stickler S, Rath B, Hamilton G
Oncol Res
. 2024 Apr;
32(5):799-805.
PMID: 38686056
Pancreatic cancer has a dismal prognosis due to late detection and lack of efficient therapies. The Kirsten rat sarcoma virus (KRAS) oncogene is mutated in up to 90% of all...
3.
Lang C, Stickler S, Rath B, Teufelsbauer M, Weigl L, Hohenegger M, et al.
Anticancer Res
. 2024 Feb;
44(3):971-980.
PMID: 38423674
Background/aim: Osteosarcoma at an advanced stage has a poor outcome, and novel targeted therapies are needed, especially for metastatic disease. Bromodomain inhibitors (BETi) are epigenetic modulators that broadly impair the...
4.
Rath B, Stickler S, Hochmair M, Hamilton G
Transl Lung Cancer Res
. 2024 Feb;
13(1):5-15.
PMID: 38405004
Background: Small cell lung cancer (SCLC) is a neuroendocrine aggressive tumor with a dismal prognosis due to the lack of curative therapeutic modalities. Approximately 11% of these patients show a...
5.
Hamilton G, Stickler S, Rath B
Curr Cancer Drug Targets
. 2024 Jan;
24(9):930-940.
PMID: 38275056
Small cell lung cancer (SCLC) has a dismal prognosis. In addition to the inactivation of the tumor suppressors TP53 and RB1, tumor-promoting MYC and paralogs are frequently overexpressed in this...
6.
Hamilton G, Stickler S, Rath B
Explor Target Antitumor Ther
. 2023 Nov;
4(5):1027-1038.
PMID: 38023987
Mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) is now a drugable oncogenic driver and the KRAS G12C variant responds clinically to sotorasib and adagrasib that covalently block the cysteine...
7.
Stickler S, Rath B, Hochmair M, Lang C, Weigl L, Hamilton G
Oncol Res
. 2023 Jun;
31(1):13-22.
PMID: 37303738
Small cell lung cancer (SCLC) is frequently disseminated and has a dismal prognosis with survival times of approximately two years. This cancer responds well to initial chemotherapy but recurs within...
8.
Rath B, Plangger A, Klameth L, Hochmair M, Ulsperger E, Boeckx B, et al.
Explor Target Antitumor Ther
. 2023 May;
4(2):355-365.
PMID: 37205313
Aim: Coagulation is frequently activated in cancer patients and has been correlated with an unfavorable prognosis. To evaluate whether a putative release of tissue factor (TF) by circulating tumor cells...
9.
Hamilton G, Rath B, Stickler S
Transl Lung Cancer Res
. 2023 May;
12(4):877-894.
PMID: 37197632
Background And Objective: In cancer patients, circulating tumor cells (CTCs) are employed as "Liquid Biopsy" for tumor detection, prognosis and assessment of the response to therapy. CTCs are responsible for...
10.
Hamilton G, Stickler S, Rath B
Curr Pharm Des
. 2023 Apr;
29(22):1741-1746.
PMID: 37073657
The most frequent mutated oncogene KRAS in lung cancer is targeted by KRAS G12C-directed drugs, such as Sotorasib and Adagrasib. Still, other alleles frequently expressed in pancreatic and colon cancer...